Rescue angioplasty versus conservative treatment or repeat thrombolysis (the REACT trial)
| ISRCTN | ISRCTN31931021 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN31931021 |
| Protocol serial number | RG/98005 |
| Sponsor | British Heart Foundation (UK) |
| Funder | British Heart Foundation (UK) (ref: RG/98005) |
- Submission date
- 16/11/2001
- Registration date
- 16/11/2001
- Last edited
- 15/07/2009
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr AH Gershlick
Scientific
Scientific
Academic Dept of Cardiology
Clinical Sciences Wing
Glenfield General Hospital
Leicester
LE3 9QP
United Kingdom
| Phone | +44 (0)116 256 3038 |
|---|---|
| agershlick@aol.com |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study acronym | REACT |
| Study objectives | Not provided at time of registration |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Myocardial infarction |
| Intervention | Patients to be randomised to: 1. Rescue Percutaneous Transluminal Coronary Angioplasty (PTCA) - stent placement or platelet glycoprotein receptor blockers and the use of intra-aortic balloon pulsation will be guided by clinical need 2. Rescue thrombolysis with tissue Plasminogen Activator (tPA), reteplase, tenecteplase 3. Conservative treatment - intravenous (iv) heparin for 24 hours |
| Intervention type | Other |
| Primary outcome measure(s) |
Not provided at time of registration |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 01/03/2004 |
| Reason abandoned (if study stopped) | Other ongoing clinical trials, as well as the introduction of the new thrombolytic agent tenecteplase (and the concomitant unlicensed use of low-molecular-weight heparin), limited the number of suitable candidates for participation. Because of declining trial recruitment and a finite funding period, the steering committee terminated enrolment in the trial in March 2004. |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Key inclusion criteria | 1. Patients with acute myocardial infarction presenting within 6 hours who have received aspirin and an accepted thrombolytic drug 2. Aged 21 - 85 years and able to give informed consent 3. Ability to undertake coronary intervention within 12 hours of onset of chest pain 4. All patients to have failed reperfusion 90 minutes from the start of thrombolysis |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/12/1999 |
| Date of final enrolment | 01/03/2004 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Academic Dept of Cardiology
Leicester
LE3 9QP
United Kingdom
LE3 9QP
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 29/12/2005 | Yes | No | |
| Results article | results | 07/07/2009 | Yes | No |
